Showing results (131-140 of 154) with videos related to

Sort By:
Pageof 16
JAMA Cardiology|July 2, 2025
Location of LMNA Variants and Clinical Outcomes in CardiomyopathyAshwin Bhaskaran, Rabah Ben Yaou, Adam S Helms, et al.
European Journal of Preventive Cardiology|October 31, 2021
External validation of the HCM Risk-Kids model for predicting sudden cardiac death in childhood hypertrophic cardiomyopathyGabrielle Norrish, Chen Qu, Ella Field, et al.
European Heart Journal|September 7, 2021
Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathyVictor Nauffal, Peter Marstrand, Larry Han, et al.
Journal of the American College of Cardiology|March 19, 2013
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathyBarry J Maron, Paolo Spirito, Michael J Ackerman, et al.
Circulation. Heart Failure|August 1, 2024
Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH TrialCatherine G Ireland, Danielle S Burstein, Sharlene M Day, et al.
Genome Medicine|January 31, 2019
Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathyRoddy Walsh, Francesco Mazzarotto, Nicola Whiffin, et al.
JACC. Heart Failure|November 9, 2024
The Clinical Trajectory of NYHA Functional Class I Patients With Obstructive Hypertrophic CardiomyopathyMonica Ahluwalia, Jiankang Liu, Iacopo Olivotto, et al.
Circulation|January 28, 2020
Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic CardiomyopathyChristopher N Toepfer, Amanda C Garfinkel, Gabriela Venturini, et al.
JAMA Cardiology|March 5, 2025
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance SubstudyJohn W Ostrominski, Brian L Claggett, Michael Jerosch-Herold, et al.
Circulation. Heart Failure|May 9, 2025
Proteomic Analysis of Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Clinical TrialConstantin-Cristian Topriceanu, Christoffer Rasmus Vissing, Anna Axelsson Raja, et al.
Pageof 16